LONDON, UK – 21 March, 2022 – Ingenion Medical Limited, today, announces it has been awarded a £277,000 SMART grant from Innovate UK, the country’s innovation agency.  The funding will support the development of a new device that will be designed to address chronic severe female incontinence.

Ingenion will use the proceeds over the next 12 months to evaluate and test a range of potential solutions that are embodied in its 2018 patent filing and incorporate design criteria gathered from clinicians and patients to develop a novel device, the FemActive™ bladder management system. a novel medical device to treat male patients suffering from chronic urinary retention.

Ingenion’s CEO Edward Cappabianca said, “Chronic, severe urinary incontinence is a debilitating condition that affects millions of women worldwide.  Currently, women are using devices that are uncomfortable, inconvenient and dehumanising, including Foley-type catheters, and absorbent pads to manage severe incontinence.  Our approach is to design products that enable patients to control their urination, without surgery or drugs. The FemActive catheter will provide women with a solution that will eliminate the need for catheters with external collection bags, or needing as many as 10 pads per day to manage their urination.  We are committed to improving the health and quality of life for men and women sufferings from urinary control dysfunctions.”

The device will be designed to work with the body’s natural defences and provide patients with a solution that is expected to reduce the incidence of Catheter Associated Urinary Tract Infections (CAUTIs), a significant contributor to hospital acquired infections and patient mortality.

Mr George Yardy, FRCS(Urol) FEBU, a urological surgeon at the East Suffolk and North Essex Foundation Trust and a founding member of Ingenion’s Medical & Scientific Advisory Board added, “This is an excellent opportunity for Ingenion to advance technology to benefit female patients who experience severe urinary incontinence.”

Dr Sergio Rothstein, Interim Chairman, “This is the second Innovate UK grant that Ingenion Medical has received in the past 15 months.  This type of non-dilutive funding is extremely helpful to innovative companies like Ingenion, as the competition for such funding is highly competitive, which demonstrates the value seen in Ingenion’s novel approach.”

About Ingenion Medical Limited:

Privately held, UK-based Ingenion Medical Limited develops, manufactures, and commercializes a family of products for chronic urinary retention and incontinence patients. CymActive™, its lead product, is a novel urinary catheter which can remain in-dwelling for up to 30 days, a dramatic quality of life improvement versus legacy solutions that often requiring multiple catheters in a single day, a common cause of infection. Visit us at:

About Innovate UK:

Innovate UK is part of UK Research and Innovation. We are the UK government’s innovation agency.  Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas.  We work with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. Find out more about what we do.


Edward Cappabianca, CEO



#medical devices

#womens health

Recent posts


LONDON, UK – Ingenion Medical Limited announces that Tim Maloney has joined the senior management of the company as Commercial Director to support the pre-commercialization activities and launch of its ground-breaking CymActive [...]
Read more
Copyright © 2024 - All Rights Reserved
Contact Ingenion Medical to find out if cymactive™️ is approved for sale in your market.